Apomine

TargetMol
Product Code: TAR-T26644
Supplier: TargetMol
CodeSizePrice
TAR-T26644-1mg1mg£189.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T26644-5mg5mg£340.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T26644-1mL1 mL * 10 mM (in DMSO)£422.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T26644-10mg10mg£470.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T26644-25mg25mg£707.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T26644-50mg50mg£978.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T26644-100mg100mg£1,291.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T26644-500mg500mg£2,456.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
Apomine, an inhibitor of HMG-CoA-reductase, promotes apoptosis of myeloma cells in vitro and has been implicated in the regulation of myeloma in vivo. Apomine accelerates the degradation of 3-hydroxy-3-methylglutaryl-CoA reductase and stimulates low-density lipoprotein receptor activity. Apomine enhances the antitumor effect of lovastatin on myeloma cells by downregulating 3-hydroxy-3-methylglutaryl-CoA reductase.
CAS:
126411-13-0
Formula:
C28H52O7P2
Molecular Weight:
562.665
Pathway:
Metabolism
Purity:
0.988
SMILES:
CC(C)OP(=O)(OC(C)C)C(Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C)P(=O)(OC(C)C)OC(C)C
Target:
HMG-CoA Reductase

References

1. Moriceau G, Roelofs AJ, Brion R, Redini F, Ebetion FH, Rogers MJ, Heymann D. Synergistic inhibitory effect of apomine and lovastatin on osteosarcoma cell growth. Cancer. 2012 Feb 1;118(3):750-60. 2. Roelofs AJ, Edwards CM, Russell RG, Ebetino FH, Rogers MJ, Hulley PA. Apomine enhances the antitumor effects of lovastatin on myeloma cells by down-regulating 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J Pharmacol Exp Ther. 2007 Jul;322(1):228-35. 3. Kuehl PJ, Stratton SP, Powell MB, Myrdal PB. Preformulation, formulation, and in vivo efficacy of topically applied apomine. Int J Pharm. 2009 Dec 1;382(1-2):104-10. doi: 10.1016/j.ijpharm.2009.08.016. PubMed PMID: 19699284; PubMed Central PMCID: PMC2783960. 4. Kuehl PJ, Stratton SP, Powell MB, Myrdal PB. Preformulation, formulation, and in vivo efficacy of topically applied apomine. Int J Pharm. 2009 Dec 1;382(1-2):104-10.